By Isabel Soisson
Nearly three years after it was signed into law, President Biden’s American Rescue Plan is still paying dividends, this time by prompting the nation’s three major insulin makers to drop their prices for the life-saving drug.
As of Jan. 1, Eli Lilly, Sanofi, and Novo Nordisk—which make up roughly 90% of the market—are all officially offering price caps and savings programs to lower the cost of some of their most widely-used insulin products to only $35 per month.
Comments